Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vanda Pharmaceuticals Inc.VNDA · Entity 5861 | Chief Corp. Affairs Officer | September 15, 2021 | September 17, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vanda Pharmaceuticals Inc.
Report date September 15, 2021 · Filed September 17, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 81,980 |
Ending reported balance
After 2021-09-15 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2021-09-15 · Exercise / conversion · Acquired 4,277 · Balance 90,962 Row 2 · 2021-09-15 · Exercise / conversion · Acquired 7,842 · Balance 98,804 Row 3 · 2021-09-15 · Sale · Disposed 16,824 · Balance 81,980 F1: A portion of the shares was sold to satisfy the exercise price and tax obligations relating to the acquisition of the shares in connection with the stock option exercise. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.40 to $16.605, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.27 · Expires 2029-07-24 | Direct | 33,224 |
Reported balance
After 2021-09-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-09-15 · Exercise / conversion · Disposed 4,277 · Balance 33,224 F3: The option vested with respect to 25% of the underlying shares on July 25, 2020, with the remaining 75% of the shares vesting in 36 equal monthly installments beginning August 25, 2020, provided the Reporting Person remains continuously employed by the Issuer through each monthly vesting date. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.32 · Expires 2030-02-25 | Direct | 47,158 |
Reported balance
After 2021-09-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-09-15 · Exercise / conversion · Disposed 7,842 · Balance 47,158 F4: The option vested with respect to 25% of the underlying shares on February 26, 2021, with the balance vesting in equal monthly installments over the next 36 months of continuous service thereafter, provided the Reporting Person remains continuously employed by the Issuer through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: A portion of the shares was sold to satisfy the exercise price and tax obligations relating to the acquisition of the shares in connection with the stock option exercise.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.40 to $16.605, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
F3: The option vested with respect to 25% of the underlying shares on July 25, 2020, with the remaining 75% of the shares vesting in 36 equal monthly installments beginning August 25, 2020, provided the Reporting Person remains continuously employed by the Issuer through each monthly vesting date.
F4: The option vested with respect to 25% of the underlying shares on February 26, 2021, with the balance vesting in equal monthly installments over the next 36 months of continuous service thereafter, provided the Reporting Person remains continuously employed by the Issuer through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 15, 2021 Filed Sep 17, 2021 12:52 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 7,842 | $0.00 Strike: $11.32 | $0.00 |
DisclosureSEC source: 0001209191-21-056530 · doc4.xml · derivative · entry 5 Jones Aranthan II · CIK 0001785894 · Chief Corp. Affairs Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,158 Underlying: Common Stock · 7,842 shares Expires 2030-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested with respect to 25% of the underlying shares on February 26, 2021, with the balance vesting in equal monthly installments over the next 36 months of continuous service thereafter, provided the Reporting Person remains continuously employed by the Issuer through the applicable vesting date. Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 12:52 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 4,277 | $0.00 Strike: $12.27 | $0.00 |
DisclosureSEC source: 0001209191-21-056530 · doc4.xml · derivative · entry 4 Jones Aranthan II · CIK 0001785894 · Chief Corp. Affairs Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,224 Underlying: Common Stock · 4,277 shares Expires 2029-07-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested with respect to 25% of the underlying shares on July 25, 2020, with the remaining 75% of the shares vesting in 36 equal monthly installments beginning August 25, 2020, provided the Reporting Person remains continuously employed by the Issuer through each monthly vesting date. Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 12:52 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 16,824 | $16.49 | $277,394.11 |
DisclosureSEC source: 0001209191-21-056530 · doc4.xml · nonDerivative · entry 3 Jones Aranthan II · CIK 0001785894 · Chief Corp. Affairs Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,980 F1 · kind: A portion of the shares was sold to satisfy the exercise price and tax obligations relating to the acquisition of the shares in connection with the stock option exercise. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.40 to $16.605, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 12:52 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionCommon Stock | 7,842 | $11.32 | $88,771.44 |
DisclosureSEC source: 0001209191-21-056530 · doc4.xml · nonDerivative · entry 2 Jones Aranthan II · CIK 0001785894 · Chief Corp. Affairs Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,804 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 12:52 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionCommon Stock | 4,277 | $12.27 | $52,478.79 |
DisclosureSEC source: 0001209191-21-056530 · doc4.xml · nonDerivative · entry 1 Jones Aranthan II · CIK 0001785894 · Chief Corp. Affairs Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,962 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 26, 2021 Filed Jul 27, 2021 20:37 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 7,250 | $19.69 | $142,776.43 |
DisclosureSEC source: 0001209191-21-048276 · doc4.xml · nonDerivative · entry 1 Jones Aranthan II · CIK 0001785894 · Chief Corp. Affairs Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,685 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.61 to $19.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| March 15, 2021 Filed Mar 16, 2021 20:20 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $11.32 | $0.00 |
DisclosureSEC source: 0001209191-21-020782 · doc4.xml · derivative · entry 3 Jones Aranthan II · CIK 0001785894 · Chief Corp. Affairs Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 15,000 shares Expires 2030-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested with respect to 25% of the underlying shares on February 26, 2021, with the balance vesting in equal monthly installments over the next 36 months of continuous service thereafter, provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date Read SEC document |
| March 15, 2021 Filed Mar 16, 2021 20:20 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 18,000 | $17.72 | $319,010.40 |
DisclosureSEC source: 0001209191-21-020782 · doc4.xml · nonDerivative · entry 2 Jones Aranthan II · CIK 0001785894 · Chief Corp. Affairs Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,935 F1 · kind: A portion of the shares were sold to satisfy the exercise price and tax obligations relating to the acquisition of the shares in connection with the stock option exercise. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.69 to $17.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| March 15, 2021 Filed Mar 16, 2021 20:20 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionCommon Stock | 15,000 | $11.32 | $169,800.00 |
DisclosureSEC source: 0001209191-21-020782 · doc4.xml · nonDerivative · entry 1 Jones Aranthan II · CIK 0001785894 · Chief Corp. Affairs Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,935 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2021 Filed Mar 3, 2021 23:40 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 3,865 | $18.04 | $69,717.26 |
DisclosureSEC source: 0001209191-21-017273 · doc4.xml · nonDerivative · entry 1 Jones Aranthan II · CIK 0001785894 · Chief Corp. Affairs Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,935 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.145, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 22:17 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 22,499 | $0.00 Strike: $12.27 | $0.00 |
DisclosureSEC source: 0001209191-21-014873 · doc4.xml · derivative · entry 5 Jones Aranthan II · CIK 0001785894 · Chief Corp. Affairs Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,501 Underlying: Common Stock · 22,499 shares Expires 2029-07-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vested and became exercisable with respect to 25% of the shares subject to the option on July 25, 2020, and the remaining 75% of the shares vests in 36 equal monthly installments beginning August 25, 2020, provided the Reporting Person remains continuously employed by the issuer through each monthly vesting date. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 22:17 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantEmployee Stock Option (Right to Buy) · Derivative | 61,200 | $0.00 Strike: $20.28 | $0.00 |
DisclosureSEC source: 0001209191-21-014873 · doc4.xml · derivative · entry 4 Jones Aranthan II · CIK 0001785894 · Chief Corp. Affairs Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,200 Underlying: Common Stock · 61,200 shares Expires 2031-02-23 F4 · derivative.exercise_date: The option vests with respect to 25% of the underlying shares on February 24, 2022, with the balance vesting in equal monthly installments over the next 36 months of continuous service thereafter, provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 22:17 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 22,986 | $20.01 | $460,032.61 |
DisclosureSEC source: 0001209191-21-014873 · doc4.xml · nonDerivative · entry 3 Jones Aranthan II · CIK 0001785894 · Chief Corp. Affairs Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,800 F2 · kind: A portion of the shares were sold to satisfy the exercise price and tax obligations relating to the acquisition of the shares in connection with the stock option exercise. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 22:17 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | Exercise / conversionCommon Stock | 22,499 | $12.27 | $276,062.73 |
DisclosureSEC source: 0001209191-21-014873 · doc4.xml · nonDerivative · entry 2 Jones Aranthan II · CIK 0001785894 · Chief Corp. Affairs Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,786 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 22:17 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 25,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-014873 · doc4.xml · nonDerivative · entry 1 Jones Aranthan II · CIK 0001785894 · Chief Corp. Affairs Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,287 F1 · price: Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2022, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 20:39 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 7,200 | $11.81 | $85,018.32 |
DisclosureSEC source: 0001209191-20-046804 · doc4.xml · nonDerivative · entry 1 Jones Aranthan II · CIK 0001785894 · Chief Corp. Affairs Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,487 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.80 to $11.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. Read SEC document |
| July 27, 2020 Filed Jul 30, 2020 00:17 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | SaleCommon Stock | 7,313 | $10.62 | $77,631.15 |
DisclosureSEC source: 0001209191-20-043998 · doc4.xml · nonDerivative · entry 1 Jones Aranthan II · CIK 0001785894 · Chief Corp. Affairs Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,687 F1 · kind: Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.48 to $10.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 23:02 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantEmployee Stock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $11.32 | $0.00 |
DisclosureSEC source: 0001209191-20-014126 · doc4.xml · derivative · entry 2 Jones Aranthan II · CIK 0001785894 · Chief Corp. Affairs Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2030-02-25 F2 · derivative.exercise_date: The option vests with respect to 25% of the underlying shares on February 26, 2021, with the balance vesting in equal monthly installments over the next 36 months of continuous service thereafter, provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 23:02 UTC | Vanda Pharmaceuticals Inc. VNDA · Entity 5861 | GrantCommon Stock | 30,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-014126 · doc4.xml · nonDerivative · entry 1 Jones Aranthan II · CIK 0001785894 · Chief Corp. Affairs Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 F1 · price: Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2021, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.